Abstract: Journal of Microbiology, Immunology and Infection (2021) 54, 109e112 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.e-jmii.com Short Communication Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia Nobuaki Mori a,*, Mitsuya Katayama a, Shigenari Nukaga b a Department of General Internal Medicine and Infectious Diseases, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan b Department of Respiratory Medicine, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan Received 13 May 2020; received in revised form 24 August 2020; accepted 9 September 2020 Available online 5 October 2020 KEYWORDS COVID-19; SARS-CoV-2; Pneumonia; Hydroxychloroquine; Azithromycin; Ciclesonide; Therapy; Reverse transcription-PCR Abstract No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy. Copyright ª 2020, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).